Resources
108 Results (showing 81 - 90)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/24/2022 (updated 3/27/2024)
In this session, we will give an overview of the program, discuss expectations, grant deliverables, and highlight trends in psychostimulant use. We will also discuss the role of the HRSA Project Officer, Grants Management Specialist, Technical Expert Leads, and Evaluation Team.
Posted 11/1/2022 (updated 3/27/2024)
Last year, the National Association of County and City Health Officials (NACCHO) launched a resource meant to help local health departments (LHD) prevent or mitigate potentially traumatic events, known as adverse childhood experiences (ACEs). The Suicide, Overdose, and Adverse Childhood Experiences Prevention Capacity Assessment Tool (SPACECAT) allows LHDs to make an internal assessment of their capacity to address and prevent a still-growing public health issue.
Posted 11/15/2022 (updated 3/27/2024)
In this decision analytical model study evaluating the distribution of 10 000 additional naloxone kits annually in Rhode Island, the strategy focusing on distribution of naloxone according to geographic need to people who inject drugs resulted in the best outcomes at the lowest cost, averting an estimated 25.3% of opioid overdose deaths at an incremental cost of $27 312 per opioid overdose death averted
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.
Posted 7/26/2023 (updated 3/28/2024)
Effective prevention includes Design, Development, and Delivery. This session addressed the critical need to follow the science, what the science is, and how the Randolph County Caring Community (RCCC) has Designed, Developed, and Delivered an evidence-based prevention system in their area. Participants learned how the PROSPER (PROmoting School-community-university Partnerships to Enhance Resilience) model has brought additional partners to its consortium, leading to the use of tested and effective prevention programs.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.